NA
MRNS

Neuburgh Advisers’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Neuburgh Advisers’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-944
Closed -$38K – 937
2018
Q3 		$38K Buy
+944
New +$26.9K ﹤0.01% 863

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Neuburgh Advisers's MRNS Position: Q4 2018 in Review

Neuburgh Advisers sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2018, closing a stake of 944 shares — an estimated $38K sold.

Neuburgh Advisers first reported a position in MRNS in Q3 2018 and held it in 1 quarter. The position peaked at $38K in Q3 2018. 90 funds tracked by Wall St. Rank hold MRNS as of Q4 2018.

  • Neuburgh Advisers reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
  • Neuburgh Advisers sold 944 Marinus Pharmaceuticals, Inc shares in Q4 2018, an estimated $38K.
  • Neuburgh Advisers first reported a position in Marinus Pharmaceuticals, Inc in Q3 2018 and held it in 1 quarter.
  • Neuburgh Advisers's Marinus Pharmaceuticals, Inc position peaked at $38K in Q3 2018.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2018.

Based on Neuburgh Advisers's 13F filing for Q4 2018, filed 13 Feb 2019.